Invivyd (IVVD) Total Liabilities (2020 - 2026)
Invivyd's (IVVD) quarterly Total Liabilities came in at $37.8 million in Q2 2026, down 18.44% on a YoY basis from $46.3 million in Q2 2025, and up 6.96% quarter-over-quarter from $35.3 million in Q4 2025.
Analysis
Invivyd (IVVD) Total Liabilities (2020 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Total Liabilities for 7 consecutive years, with $37.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Liabilities fell 18.44% year-over-year to $37.8 million; the trailing twelve-month figure through Jun 2026 stood at $37.8 million (down 18.44% YoY), and the FY2025 full-year result was $35.3 million, down 42.97% from the prior year.
- Total Liabilities advanced to $37.8 million in Q2 2026 per IVVD's latest filing, from $35.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $96.9 million in Q1 2022 and bottomed at $23.8 million in Q1 2023.
- Historically, Total Liabilities has averaged $47.6 million across 5 years, with a median of $46.1 million in 2025.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities tumbled 75.42% in 2023, then jumped 177.15% in 2024.
- Over 5 years, Total Liabilities stood at $27.2 million in 2022, then jumped by 90.14% to $51.7 million in 2023, then advanced by 19.85% to $62.0 million in 2024, then tumbled by 42.97% to $35.3 million in 2025, then advanced by 6.96% to $37.8 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $37.8 million, $35.3 million, and $46.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | 37.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 37.80 Mn |
| Dec 31, 2025 | 35.34 Mn |
| Sep 30, 2025 | 46.09 Mn |
| Jun 30, 2025 | 46.35 Mn |
| Mar 31, 2025 | 49.60 Mn |
| Dec 31, 2024 | 61.98 Mn |
| Sep 30, 2024 | 78.76 Mn |
| Jun 30, 2024 | 36.70 Mn |
| Mar 31, 2024 | 36.97 Mn |
| Dec 31, 2023 | 51.71 Mn |
| Sep 30, 2023 | 28.42 Mn |
| Jun 30, 2023 | 33.85 Mn |
| Mar 31, 2023 | 23.82 Mn |
| Dec 31, 2022 | 27.20 Mn |
| Sep 30, 2022 | 47.30 Mn |
| Jun 30, 2022 | 69.77 Mn |
| Mar 31, 2022 | 96.88 Mn |
| Dec 31, 2021 | 62.07 Mn |
| Sep 30, 2021 | 53.06 Mn |
| Jun 30, 2021 | 37.91 Mn |